In the present work, the enhancement of biogas and methane yields through anaerobic co-digestion of the pre-hydrolised Organic Fraction of Municipal Solid Wastes (hOFMSW) and Maize Cob Wastes (MCW) in a lab-scale thermophilic anaerobic reactor was tested. In order to increase its biodegradability, MCW were submitted to an initial pre-treatment screening phase as follows: (i) microwave (MW) irradiation catalysed by NaOH, (ii) MW catalysed by glycerol in water and alkaline water solutions, (iii) MW catalysed by HO with pH of 9.8 and (iv) chemical pre-treatment at room temperature catalysed by HO with 4 h reaction time. The pre-treatments cataysed by HO were performed with 2% MCW (wMCW/v alkaline water) at ratios of 0.125, 0.25, 0.5 and 1.0 (wHO/wMCW). The pre-treatment that presented the most favourable balance between sugars, lignin, cellulose and hemicellulose solubilisations, as well as low production of phenolic compound and furfural (inhibitors), was the chemical pre-treatment catalysed by HO, at room temperature, with a ratio of 0.5 wHO/wMCW (Pre1). This Pre1 was then optimised testing reaction times of 1, 2 and 3 days at a different pH (11.5) and MCW percentage (10% w/v). The optimised pre-treatment that presented the best results, considering the same criteria defined above, was the one carried out during 3 days, at pH 9.8 and 10% MCW w/v (Pre2). The anaerobic reactor was initially fed with the hOFMSW obtained from the hydrolysis tank of an industrial AD plant. The hOFMSW was than co-digested with MCW submitted to the pre-treatment Pre1. In another assay, hOFMSW was co-digested with MCW submitted pre-treatment Pre 2. The co-digestion of hOFMSW + Pre1 increased the biogas yield by 38.9% and methane yield by 29.7%, when compared to the results obtained with hOFMSW alone. The co-digestion of hOFMSW + Pre2 increased biogas yield by 46.0% and CH yield by 36.3%. In both cases, the methane content obtained in the biogas streams was above 66% v/v. These results show that pre-treatment with HO, at room temperature, is a promising low cost way to valorize MCW through co-digestion with hOFMSW.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.wasman.2017.11.004 | DOI Listing |
Injury
November 2024
Division of Trauma and Critical Care, Medical College of Wisconsin, 8701 Watertown Plank Rd. Milwaukee, WI 53226, United States. Electronic address:
Background: Although treatments have improved dramatically in recent years, mortality following gunshot wounds (GSW) to the pelvis continue to range between 3 and 20 %. This project was designed to determine the incidence and risk factors associated with pelvic fracture-related infection (FRI) following GSWs to the pelvis given the paucity of evidence regarding this complication.
Methods: A retrospective review of 13 years (1/2010-12/2022) of patients with GSW to the pelvis was performed.
Cancer Manag Res
September 2024
Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Metastatic castrate-resistant prostate cancer (mCRPC) is associated with poor prognosis. DNA damage response (DDR) genes are commonly altered in mCRPC rendering them as promising therapeutic targets. Poly (ADP ribose) polymerase inhibitors (PARPi) demonstrated antitumor activity in mCRPC patients with DDR gene mutations through synthetic lethality.
View Article and Find Full Text PDFClin Genitourin Cancer
December 2024
Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI. Electronic address:
Open Heart
August 2024
Centre for Cardiovascular Science, The University of Edinburgh, Edinburgh, UK
Background: Guidelines recommend the use of risk scores to select patients for further investigation after myocardial infarction has been ruled out but their utility to identify those with coronary artery disease is uncertain.
Methods: In a prospective cohort study, patients with intermediate high-sensitivity cardiac troponin I concentrations (5 ng/L to sex-specific 99th percentile) in whom myocardial infarction was ruled out were enrolled and underwent coronary CT angiography (CCTA) after hospital discharge. History, ECG, Age, Risk factors, Troponin (HEART), Emergency Department Assessment of Chest Pain Score (EDACS), Global Registry of Acute Coronary Event (GRACE), Thrombolysis In Myocardial Infarction (TIMI), Systematic COronary Risk Evaluation 2 and Pooled Cohort Equation risk scores were calculated and the odds ratio (OR) and diagnostic performance for obstructive coronary artery disease were determined using established thresholds.
J Immunother Cancer
July 2024
Medical College of Wisconsin, Milwaukee, Wisconsin, USA
Objectives: Multiple common cancers benefit from immunotherapy; however, less is known about efficacy in rare tumors. We report the results of the adrenocortical carcinoma cohort of NCI/SWOG S1609 Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors.
Design/setting: A prospective, phase 2 clinical trial of ipilimumab plus nivolumab was conducted by the SWOG Early Therapeutics and Rare Cancers Committee for multiple rare tumor cohorts across >1,000 National Clinical Trial Network sites.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!